Nifty
:
17196.70
Sensex
:
57696.46
-204.95 (-1.18%)
-764.83 (-1.31%)
Nifty
Sensex
:
:
17196.70
57696.46
-204.95 (-1.18%)
-764.83 (-1.31%)

Morepen Laboratories Ltd.

Pharmaceuticals & Drugs - API

Rating :
50/99

BSE: 500288 | NSE: MOREPENLAB

NSE BSE
52.65
03-Dec-2021
  • Open
  • High
  • Low
  • Previous Close
  •  50.50
  •  53.45
  •  50.50
  •  51.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  3549573
  •  1858.03
  •  75.00
  •  26.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,366.09
  • 19.99
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 2,315.24
  • N/A
  • 4.81

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 34.54%
  • 2.86%
  • 44.82%
  • FII
  • DII
  • Others
  • 0.86%
  • 1.13%
  • 15.79%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.17
  • 14.81
  • 15.63

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.94
  • 14.07
  • 11.91

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 32.66
  • 49.86

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.05
  • 29.95
  • 23.89

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.33
  • 4.56
  • 3.94

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.92
  • 15.07
  • 13.12

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Net Sales
395.31
336.39
17.52%
386.73
257.64
50.10%
286.60
206.60
38.72%
307.42
230.06
33.63%
Expenses
353.29
304.64
15.97%
342.88
231.07
48.39%
256.20
187.78
36.44%
277.63
214.75
29.28%
EBITDA
42.03
31.75
32.38%
43.85
26.57
65.04%
30.40
18.83
61.44%
29.79
15.30
94.71%
EBIDTM
10.63%
9.44%
11.34%
10.31%
10.61%
9.11%
9.69%
6.65%
Other Income
2.85
3.73
-23.59%
1.58
1.33
18.80%
4.16
1.79
132.40%
2.84
4.60
-38.26%
Interest
-9.12
0.29
-
0.21
0.29
-27.59%
-0.05
0.62
-
1.27
0.54
135.19%
Depreciation
7.14
7.68
-7.03%
6.69
8.06
-17.00%
6.98
8.63
-19.12%
7.56
8.54
-11.48%
PBT
46.86
27.52
70.28%
38.53
19.55
97.08%
27.64
11.36
143.31%
23.80
10.82
119.96%
Tax
9.50
0.35
2,614.29%
8.06
0.19
4,142.11%
0.87
0.34
155.88%
0.01
0.01
0.00%
PAT
37.36
27.17
37.50%
30.47
19.37
57.31%
26.76
11.02
142.83%
23.79
10.82
119.87%
PATM
9.45%
8.08%
7.88%
7.52%
9.34%
5.33%
7.74%
4.70%
EPS
0.83
0.60
38.33%
0.68
0.43
58.14%
0.59
0.25
136.00%
0.53
0.24
120.83%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
1,376.06
1,188.06
853.07
768.54
606.51
595.47
485.08
400.64
366.85
325.92
289.34
Net Sales Growth
33.51%
39.27%
11.00%
26.72%
1.85%
22.76%
21.08%
9.21%
12.56%
12.64%
 
Cost Of Goods Sold
922.55
735.29
524.19
479.12
361.28
358.35
293.33
238.62
209.04
193.53
178.07
Gross Profit
453.51
452.77
328.87
289.42
245.23
237.12
191.76
162.02
157.81
132.39
111.27
GP Margin
32.96%
38.11%
38.55%
37.66%
40.43%
39.82%
39.53%
40.44%
43.02%
40.62%
38.46%
Total Expenditure
1,230.00
1,069.54
784.55
701.02
541.78
534.09
423.52
352.41
317.95
294.97
270.11
Power & Fuel Cost
-
13.00
12.56
13.18
11.08
9.84
7.64
7.41
8.42
8.96
9.82
% Of Sales
-
1.09%
1.47%
1.71%
1.83%
1.65%
1.57%
1.85%
2.30%
2.75%
3.39%
Employee Cost
-
135.59
109.91
95.36
76.53
69.69
58.29
48.79
45.08
39.17
36.05
% Of Sales
-
11.41%
12.88%
12.41%
12.62%
11.70%
12.02%
12.18%
12.29%
12.02%
12.46%
Manufacturing Exp.
-
67.21
48.92
31.28
16.21
22.36
13.33
12.68
12.23
11.33
10.20
% Of Sales
-
5.66%
5.73%
4.07%
2.67%
3.76%
2.75%
3.16%
3.33%
3.48%
3.53%
General & Admin Exp.
-
34.71
36.47
36.14
28.52
18.11
18.14
15.89
16.62
13.86
14.37
% Of Sales
-
2.92%
4.28%
4.70%
4.70%
3.04%
3.74%
3.97%
4.53%
4.25%
4.97%
Selling & Distn. Exp.
-
49.66
40.11
32.73
30.04
25.79
23.45
21.40
19.55
20.40
15.85
% Of Sales
-
4.18%
4.70%
4.26%
4.95%
4.33%
4.83%
5.34%
5.33%
6.26%
5.48%
Miscellaneous Exp.
-
34.08
12.39
13.20
18.11
29.95
9.35
7.61
7.01
7.72
15.85
% Of Sales
-
2.87%
1.45%
1.72%
2.99%
5.03%
1.93%
1.90%
1.91%
2.37%
1.99%
EBITDA
146.07
118.52
68.52
67.52
64.73
61.38
61.56
48.23
48.90
30.95
19.23
EBITDA Margin
10.62%
9.98%
8.03%
8.79%
10.67%
10.31%
12.69%
12.04%
13.33%
9.50%
6.65%
Other Income
11.43
12.07
9.48
3.67
3.72
3.72
1.20
1.37
1.22
2.87
1.18
Interest
-7.69
1.79
1.98
2.11
4.36
7.56
10.50
8.66
9.92
11.63
7.96
Depreciation
28.37
30.28
36.91
39.90
34.32
33.90
35.20
38.67
45.84
45.80
48.06
PBT
136.83
98.51
39.11
29.18
29.77
23.63
17.06
2.28
-5.64
-23.61
-35.61
Tax
18.44
1.42
5.53
0.34
0.00
0.00
-0.13
0.14
0.01
-0.01
0.06
Tax Rate
13.48%
1.44%
14.14%
1.17%
0.00%
0.00%
-1.03%
6.14%
-0.36%
0.05%
-0.25%
PAT
118.38
97.09
33.58
28.85
29.59
23.63
12.80
2.14
-2.77
-20.52
-23.65
PAT before Minority Interest
118.37
97.09
33.58
28.84
29.77
23.63
12.80
2.14
-2.75
-20.52
-23.63
Minority Interest
-0.01
0.00
0.00
0.01
-0.18
0.00
0.00
0.00
-0.02
0.00
-0.02
PAT Margin
8.60%
8.17%
3.94%
3.75%
4.88%
3.97%
2.64%
0.53%
-0.76%
-6.30%
-8.17%
PAT Growth
73.12%
189.13%
16.40%
-2.50%
25.22%
84.61%
498.13%
-
-
-
 
EPS
2.63
2.16
0.75
0.64
0.66
0.53
0.28
0.05
-0.06
-0.46
-0.53

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
424.75
284.06
253.09
225.94
196.26
300.28
287.48
297.11
299.88
320.40
Share Capital
89.96
89.96
89.96
89.96
89.96
209.61
209.61
209.61
209.61
209.61
Total Reserves
291.04
194.10
163.13
135.98
106.30
90.67
77.87
87.50
90.27
110.79
Non-Current Liabilities
30.06
28.42
23.38
20.20
17.80
57.47
74.00
84.65
103.91
122.05
Secured Loans
0.83
0.92
1.83
2.95
1.38
43.41
62.27
74.78
94.65
98.85
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
15.04
Long Term Provisions
25.39
23.82
19.01
14.42
13.59
11.34
9.22
7.82
7.17
5.73
Current Liabilities
403.80
351.44
339.17
340.12
324.86
166.56
127.92
108.14
102.73
104.95
Trade Payables
208.85
172.30
168.15
174.88
124.88
115.33
84.96
68.60
56.81
64.98
Other Current Liabilities
174.38
165.06
160.64
163.90
198.65
47.04
39.87
37.58
45.22
38.96
Short Term Borrowings
15.32
11.36
8.99
0.00
0.00
0.00
2.23
1.19
0.00
0.00
Short Term Provisions
5.25
2.72
1.39
1.33
1.33
4.19
0.86
0.77
0.70
1.01
Total Liabilities
858.15
663.46
615.18
585.81
538.29
523.68
489.00
489.50
506.09
546.98
Net Block
224.52
216.37
236.21
264.29
271.80
296.72
322.48
368.08
409.46
451.86
Gross Block
628.32
752.55
887.76
997.60
1,026.96
1,018.43
1,009.35
1,004.61
1,000.44
997.38
Accumulated Depreciation
403.79
536.18
651.55
733.31
755.15
721.72
686.87
636.53
590.98
545.52
Non Current Assets
331.36
291.29
315.71
342.37
346.34
366.53
374.42
393.18
415.00
457.37
Capital Work in Progress
1.96
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Non Current Investment
1.08
1.08
0.00
0.00
0.00
0.00
0.00
0.00
3.87
3.87
Long Term Loans & Adv.
103.52
73.55
79.22
77.81
73.69
69.82
51.94
25.10
1.67
1.64
Other Non Current Assets
0.27
0.28
0.28
0.27
0.85
0.00
0.00
0.00
0.00
0.00
Current Assets
526.79
372.18
299.47
243.44
191.95
157.15
114.58
96.32
91.09
89.61
Current Investments
0.00
0.00
0.02
0.22
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
175.33
138.48
94.20
76.89
64.66
42.14
37.11
33.30
37.05
38.66
Sundry Debtors
181.98
137.68
133.75
121.85
92.95
87.94
56.14
42.67
39.11
35.15
Cash & Bank
67.89
38.88
32.21
5.95
7.59
4.36
8.85
9.11
5.53
4.51
Other Current Assets
101.59
5.98
7.86
5.62
26.74
22.71
12.48
11.24
9.40
11.29
Short Term Loans & Adv.
91.58
51.16
31.43
32.92
22.03
16.77
9.34
8.23
6.23
9.60
Net Current Assets
122.99
20.73
-39.70
-96.68
-132.92
-9.41
-13.34
-11.82
-11.64
-15.34
Total Assets
858.15
663.47
615.18
585.81
538.29
523.68
489.00
489.50
506.09
546.98

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
50.83
11.02
17.37
63.41
40.73
50.07
50.70
33.52
33.64
27.11
PBT
98.51
39.11
29.18
29.77
23.04
17.06
2.28
-5.64
-23.60
-35.61
Adjustment
31.96
36.63
40.32
38.64
41.40
45.69
47.32
55.76
56.80
55.99
Changes in Working Capital
-78.18
-58.84
-51.78
-5.00
-23.72
-8.41
1.23
-19.50
-2.64
-5.25
Cash after chg. in Working capital
52.29
16.89
17.71
63.41
40.73
54.34
50.83
30.62
30.56
15.13
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1.46
-5.88
-0.34
0.00
0.00
0.13
-0.13
0.01
0.01
-0.06
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
-4.40
0.00
0.00
0.00
0.00
Cash From Investing Activity
-70.35
-12.46
-13.05
-26.93
-13.60
-27.30
-31.65
-0.80
-2.83
-3.35
Net Fixed Assets
123.41
135.60
113.16
31.96
-8.08
-7.02
-4.73
-4.09
-2.87
0.60
Net Investments
0.00
-1.07
0.20
-0.22
0.00
0.25
0.00
3.87
0.00
0.10
Others
-193.76
-146.99
-126.41
-58.67
-5.52
-20.53
-26.92
-0.58
0.04
-4.05
Cash from Financing Activity
47.27
5.49
-0.44
-37.77
-23.72
-27.26
-19.31
-29.14
-29.79
-21.83
Net Cash Inflow / Outflow
27.75
4.04
3.88
-1.29
3.40
-4.49
-0.26
3.58
1.02
1.93
Opening Cash & Equivalents
13.64
9.60
5.72
7.00
3.60
8.85
9.11
5.53
4.51
2.58
Closing Cash & Equivalent
41.39
13.64
9.60
5.72
7.00
4.36
8.85
9.11
5.53
4.51

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
8.47
6.32
5.63
5.02
4.36
4.02
3.73
3.95
4.01
4.46
ROA
12.76%
5.25%
4.80%
5.30%
4.45%
2.53%
0.44%
-0.55%
-3.90%
-4.19%
ROE
29.20%
12.50%
12.04%
14.10%
12.54%
7.35%
1.24%
-1.54%
-10.77%
-11.12%
ROCE
27.13%
12.05%
10.01%
14.05%
10.18%
6.29%
2.90%
1.80%
-2.09%
-3.40%
Fixed Asset Turnover
1.72
1.04
0.82
0.60
0.58
0.49
0.41
0.37
0.33
0.29
Receivable days
49.10
58.07
60.70
64.63
55.44
53.22
44.17
40.16
40.83
40.35
Inventory Days
48.20
49.78
40.63
42.59
32.73
29.27
31.48
34.55
41.63
45.68
Payable days
66.26
79.06
88.85
103.38
82.97
83.88
76.01
67.69
69.30
75.59
Cash Conversion Cycle
31.05
28.78
12.48
3.85
5.20
-1.39
-0.36
7.02
13.16
10.44
Total Debt/Equity
0.04
0.05
0.52
0.06
0.25
0.22
0.28
0.30
0.37
0.38
Interest Cover
56.09
20.71
14.83
7.83
4.13
2.21
1.26
0.72
-0.77
-1.96

Annual Reports:

FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012

News Update:


  • Morepen Laboratories gets USFDA’s nod for anti-allergy drug Fexofinadine Hydrochloride
    3rd Dec 2021, 12:43 PM

    Fexofinadine is most widely used, second generation antihistamine drug for the treatment of allergy symptoms and hay fever

    Read More
  • Morepen Laboratories - Quarterly Results
    11th Nov 2021, 13:46 PM

    Read More
  • Morepen Laboratories carves out Medical Devices into subsidiary
    29th Sep 2021, 09:18 AM

    The shareholders have given their approval for the same on September 28, 2021 in the 36th AGM of the company

    Read More
  • Morepen Laboratories incorporates wholly owned subsidiary company
    7th Sep 2021, 15:58 PM

    The company has incorporated a wholly owned subsidiary namely ‘Morepen Devices’on September 06, 2021

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.